This study explores patient-reported outcomes #PROs for patients with previously treated #SCLC receiving #Tarlatamab, a bispecific T-cell engager binding #DLL3 and #CD3

@natureportfolio.nature.com

#Onco404 #Cancer #Kanser #LungCancer #ClinicalTrials #Immunotherapy #BispesificAntibody #MedSky